Matches in SemOpenAlex for { <https://semopenalex.org/work/W2200319253> ?p ?o ?g. }
- W2200319253 endingPage "320" @default.
- W2200319253 startingPage "1" @default.
- W2200319253 abstract "Background The efficacy of infliximab and ciclosporin in treating severe ulcerative colitis (UC) is proven, but there has been no comparative evaluation of effectiveness. Objective To compare the clinical effectiveness and cost-effectiveness of infliximab and ciclosporin in treating steroid-resistant acute severe UC. Method Between May 2010 and February 2013 we recruited 270 participants from 52 hospitals in England, Scotland and Wales to an open-label parallel-group, pragmatic randomised trial. Consented patients admitted with severe colitis completed baseline quality-of-life questionnaires before receiving intravenous hydrocortisone. If they failed to respond within about 5 days, and met other inclusion criteria, we invited them to participate and used a web-based adaptive randomisation algorithm to allocate them in equal proportions between 5 mg/kg of intravenous infliximab at 0, 2 and 6 weeks or 2 mg/kg/day of intravenous ciclosporin for 7 days followed by 5.5 mg/kg/day of oral ciclosporin until 12 weeks from randomisation. Further treatment was at the discretion of physicians responsible for clinical management. The primary outcome was quality-adjusted survival (QAS): the area under the curve (AUC) of scores derived from Crohn’s and Ulcerative Colitis Questionnaires completed by participants at 3 and 6 months, and then 6-monthly over 1–3 years, more frequently after surgery. Secondary outcomes collected simultaneously included European Quality of Life-5 Dimensions (EQ-5D) scores and NHS resource use to estimate cost-effectiveness. Blinding was possible only for data analysts. We interviewed 20 trial participants and 23 participating professionals. Funded data collection finished in March 2014. Most participants consented to complete annual questionnaires and for us to analyse their routinely collected health data over 10 years. Results The 135 participants in each group were well matched at baseline. In 121 participants analysed in each group, we found no significant difference between infliximab and ciclosporin in QAS [mean difference in AUC/day 0.0297 favouring ciclosporin, 95% confidence interval (CI) –0.0088 to 0.0682; p = 0.129]; EQ-5D scores (quality-adjusted life-year mean difference 0.021 favouring ciclosporin, 95% CI –0.032 to 0.096; p = 0.350); Short Form questionnaire-6 Dimensions scores (mean difference 0.0051 favouring ciclosporin, 95% CI –0.0250 to 0.0353; p = 0.737). There was no statistically significant difference in colectomy rates [odds ratio (OR) 1.350 favouring infliximab, 95% CI 0.832 to 2.188; p = 0.223]; numbers of serious adverse reactions (event ratio = 0.938 favouring ciclosporin, 95% CI 0.590 to 1.493; p = 0.788); participants with serious adverse reactions (OR 0.660 favouring ciclosporin, 95% CI 0.282 to 1.546; p = 0.338); numbers of serious adverse events (event ratio 1.075 favouring infliximab, 95% CI 0.603 to 1.917; p = 0.807); participants with serious adverse events (OR 0.999 favouring infliximab, 95% CI 0.473 to 2.114; p = 0.998); deaths (all three who died received infliximab; p = 0.247) or concomitant use of immunosuppressants. The lower cost of ciclosporin led to lower total NHS costs (mean difference –£5632, 95% CI –£8305 to –£2773; p < 0.001). Interviews highlighted the debilitating effect of UC; participants were more positive about infliximab than ciclosporin. Professionals reported advantages and disadvantages with both drugs, but nurses disliked the intravenous ciclosporin. Conclusions Total cost to the NHS was considerably higher for infliximab than ciclosporin. Nevertheless, there was no significant difference between the two drugs in clinical effectiveness, colectomy rates, incidence of SAEs or reactions, or mortality, when measured 1–3 years post treatment. To assess long-term outcome participants will be followed up for 10 years post randomisation, using questionnaires and routinely collected data. Further studies will be needed to evaluate the efficacy and effectiveness of new anti-tumour necrosis factor drugs and formulations of ciclosporin. Trial registration Current Controlled Trials ISRCTN22663589. Funding This project was funded by the NIHR Health Technology Assessment programme and will be published in full in Health Technology Assessment ; Vol. 20, No. 44. See the NIHR Journals Library website for further project information." @default.
- W2200319253 created "2016-06-24" @default.
- W2200319253 creator A5000583117 @default.
- W2200319253 creator A5025926649 @default.
- W2200319253 creator A5029331185 @default.
- W2200319253 creator A5035096226 @default.
- W2200319253 creator A5042728758 @default.
- W2200319253 creator A5046013304 @default.
- W2200319253 creator A5050747579 @default.
- W2200319253 creator A5060180010 @default.
- W2200319253 creator A5061756255 @default.
- W2200319253 creator A5070061072 @default.
- W2200319253 creator A5072310133 @default.
- W2200319253 creator A5086247686 @default.
- W2200319253 creator A5088183223 @default.
- W2200319253 date "2016-06-01" @default.
- W2200319253 modified "2023-10-13" @default.
- W2200319253 title "Comparison Of iNfliximab and ciclosporin in STeroid Resistant Ulcerative Colitis: pragmatic randomised Trial and economic evaluation (CONSTRUCT)" @default.
- W2200319253 cites W1487976653 @default.
- W2200319253 cites W1526363547 @default.
- W2200319253 cites W1547450212 @default.
- W2200319253 cites W1562415841 @default.
- W2200319253 cites W1571943320 @default.
- W2200319253 cites W1575714269 @default.
- W2200319253 cites W1593679868 @default.
- W2200319253 cites W1607808246 @default.
- W2200319253 cites W1615260328 @default.
- W2200319253 cites W1669870 @default.
- W2200319253 cites W1702272919 @default.
- W2200319253 cites W1748466511 @default.
- W2200319253 cites W1840068411 @default.
- W2200319253 cites W1963569206 @default.
- W2200319253 cites W1968921516 @default.
- W2200319253 cites W1969387826 @default.
- W2200319253 cites W1970524014 @default.
- W2200319253 cites W1974242080 @default.
- W2200319253 cites W1981640880 @default.
- W2200319253 cites W1982998071 @default.
- W2200319253 cites W1985209162 @default.
- W2200319253 cites W1987448982 @default.
- W2200319253 cites W1987925515 @default.
- W2200319253 cites W1991494239 @default.
- W2200319253 cites W1995207717 @default.
- W2200319253 cites W2007433561 @default.
- W2200319253 cites W2009940024 @default.
- W2200319253 cites W2010225342 @default.
- W2200319253 cites W2014544360 @default.
- W2200319253 cites W2019136914 @default.
- W2200319253 cites W2020708502 @default.
- W2200319253 cites W2022888597 @default.
- W2200319253 cites W2023262456 @default.
- W2200319253 cites W2029465592 @default.
- W2200319253 cites W2032541700 @default.
- W2200319253 cites W2034093184 @default.
- W2200319253 cites W2045476617 @default.
- W2200319253 cites W2051123343 @default.
- W2200319253 cites W2053491820 @default.
- W2200319253 cites W2053574289 @default.
- W2200319253 cites W2054802177 @default.
- W2200319253 cites W2055461186 @default.
- W2200319253 cites W2062443774 @default.
- W2200319253 cites W2063484658 @default.
- W2200319253 cites W2064383441 @default.
- W2200319253 cites W2070299891 @default.
- W2200319253 cites W2071644653 @default.
- W2200319253 cites W2071686284 @default.
- W2200319253 cites W2077882626 @default.
- W2200319253 cites W2079852247 @default.
- W2200319253 cites W2080715613 @default.
- W2200319253 cites W2085136989 @default.
- W2200319253 cites W2085161424 @default.
- W2200319253 cites W2089991488 @default.
- W2200319253 cites W2093375795 @default.
- W2200319253 cites W2095168343 @default.
- W2200319253 cites W2096256540 @default.
- W2200319253 cites W2099169909 @default.
- W2200319253 cites W2102013054 @default.
- W2200319253 cites W2103050789 @default.
- W2200319253 cites W2110431279 @default.
- W2200319253 cites W2111362292 @default.
- W2200319253 cites W2113173442 @default.
- W2200319253 cites W2115020173 @default.
- W2200319253 cites W2115509137 @default.
- W2200319253 cites W2121260893 @default.
- W2200319253 cites W2124185266 @default.
- W2200319253 cites W2125828692 @default.
- W2200319253 cites W2127315329 @default.
- W2200319253 cites W2136657367 @default.
- W2200319253 cites W2137428428 @default.
- W2200319253 cites W2142220532 @default.
- W2200319253 cites W2143710323 @default.
- W2200319253 cites W2145135012 @default.
- W2200319253 cites W2160889655 @default.
- W2200319253 cites W2161740442 @default.
- W2200319253 cites W2162450210 @default.
- W2200319253 cites W2164153707 @default.
- W2200319253 cites W2168360361 @default.
- W2200319253 cites W2169912308 @default.